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SHORT REPORT
Gonadotrophin-releasing hormone (GnRH) analogues in the
treatment of mixed Mullerian tumours of the uterus: two case
reports and review
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Department of Obstetrics & Gynaecology, King’s College Hospital, London SE5 9RS, UK
Abstract
Subjects/Discussion. Two cases of clinical and radiological response of recurrent mixed Mullerian tumours following
treatment with either nasal (Buserilin) or intramuscular (Goserilin) GnRH analogues are reported and a short review of
the evidence to support this treatment option presented.
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Introduction
Mixed Mullerian tumours, derived from the mes-
enchymal remnants of the urogenital ridge and
epithelium originating from the coelomic cavity, are
rare but usually rapidly fatal uterine tumours of
post-reproductive women. Recurrence after surgery
is common even in apparently early disease and
survival despite subsequent radiotherapy or chemo-
therapy extremely poor.
The in vitro ® nding of GnRH receptors on some
tumour lines led us to try treatment with nasal
GnRH analogues in two patients with some
signi® cant, albeit temporary, success.
Case 1
A 70 year-old mother of eight children, presented in
April 1993 with a short history of post menopausal-
bleeding. She had passed through the menopause
aged 38 and had never taken hormone replacement
therapy. Her past medical history included recently
diagnosed non-insulin dependent diabetes mellitus
with nothing else of relevance.
There was no evidence of uterine enlargement on
examination, but Vabra curettage suggested a het-
erologous malignant mixed Mullerian tumour (Car-
cinosarcoma) and she subsequently underwent a
total abdominal hysterectomy with bilateral salp-
ingo-oophorectomy and omentectomy. There was
no evidence of extra-uterine spread at laparotomy
and histology con® rmed a poorly differentiated car-
cinosarcoma with no myometrial invasion (Stage
1a).
Despite the early stage at presentation, within a
year (March 1994) she developed pelvic pain associ-
ated with a palpable vaginal mass. A CT scan
con® rmed a soft tissue mass 4 3 5 cm above the
vaginal vault causing partial right ureteric obstruc-
Fig. 1. CT scan (pelvis) of patient (Case 1) before treatment
with a GnRH analogue demonstrating a right-sided mass of
recurrent tumour (arrowed) causing ureteric obstruction.
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Fig. 2. MRI scan (pelvis) of patient (Case 1) three months after
commencing treatment with a GnRH analogue demonstrating
central necrosis of tumour with no signi® cant enlargement
(arrowed).
1996. From February 1996 there was rapid local
growth in the pelvis and she died from obstructive
renal failure in April 1996.
Case 2
A 49 year-old mother of two was referred from a
menopause clinic with a short history of irregular
vaginal bleeding on combined hormone replacement
therapy, which she had taken for ® ve years. She had
a complex past medical history featuring several
operations for adenocarcinoma of the bowel (com-
plicating polyposis coli), culminating in a panproc-
tocolectomy with ileostomy formation in 1986. A
further operation for bowel obstruction had taken
place in 1989, with no evidence of tumour recur-
rence.
Vabra curettings obtained on 5 July 1993 demon-
strated apparently poorly differentiated adeno-
carcinoma of endometrial origin, but
immunocytochemistry of the subsequent hyster-
ectomy specimen con® rmed a heterologous malig-
nant mixed mesodermal tumour. Tumour volume
was small and in® ltration con® ned to the super® cial
myometrium only (Stage 1b).
After some initial complications arising from her
previous extensive pelvic surgery, she remained well
until December 1994, when she developed pelvic
pain and haematuria associated with a pelvic mass.
MRI scanning con® rmed a 5 3 5 cm vault mass
extending to S3, with no pelvic lymphadenopathy.
Subsequent cystoscopy excluded invasive tumour in
the bladder.
She was commenced on Goserelin acetate 3.6
mg/28 days in February 1994. There was rapid
clinical regression, and both a CT scan and MRI
performed in June 1994 showed no evidence of
tumour progression.
After completing six cycles of Goserilin she
remained in remission until November 1994, when
increasing pelvic and low back pain was found to be
associated with radiological recurrence. She was
commenced on salvage radiotherapy (Mid plain
dose of 40 Gy in 20 daily fractions); despite some
initial success in symptom reduction, she developed
recurrent small bowel obstruction associated with
progressive left iliac lymphadenopathy. The former
was thought more likely to be due to surgical adhe-
sions rather than tumour, and with careful dietary
adjustment and pain control she remained reason-
ably well until April 1996.
Increasing back pain was associated with tumour
re-growth and was treated with three cycles of
Cyclophosphamide (Farmitalia, UK) and Cisplatin
(Farmitalia, UK) in early 1996; clinically there was
a partial response, but radiological con® rmation was
dif® cult because of her previous surgery. Incontro-
vertible evidence of tumour progression was, how-
ever, shown on PET scanning in March 1997, and
she is currently managed on MST 300 mg bd,
Fig. 3. MRI scan (pelvis) of patient (Case 1) three months after
completing treatment with a GnRH analogue. Post-treatment
evidence of enlargement is now present (arrowed) but areas of
central necrosis persist and there is compression rather than
invasion of local structures.
tion and right-sided pelvic lymphadenopathy
extending to the para caval region (Fig. 1).
In view of her pain and the rapid return of disease
she was commenced on Goserelin acetate 3.6 mg/28
days (Zoladex, ICI, UK) with rapid resolution of
symptoms. Pelvic examination was normal in June
1994 and magnetic resonance imaging (MRI) per-
formed the same month showed no signi® cant
increase in tumour size or progression of the pelvic
lymphadenopathy (Fig. 2).
She remained in both radiological and clinical
remission and completed the six-month course of
treatment. Further MRI assessment in December
1994 showed evidence of central necrosis in the
tumour mass and no lymphadenopathy (Fig. 3).
In March 1995 a further episode of vaginal bleed-
ing heralded the return of progressive tumour. An
offensive polypoid tumour arising from the vaginal
vault was excised and combined radiotherapy and
nasal Buserelin acetate 150 m g TDS (Suprecur,
Hoeschst, UK) suppressed her disease until earlyGnRH analogues in treatment of mixed Mullerian tumours 199




component Benign Malignant Tumour type
Benign Adeno® broma Adenosarcoma Homologous
Undescribed Adenosarcoma Heterologous
Malignant Carcino® broma Carcinosarcoma Homologous
Carcinomesenchymoma Carcinosarcoma Heterologous
Amitriptyline 10 mg nocte and Oromorph 40 mg as
required.
Discussion
Mixed Mullerian tumours are traditionally divided
into two groups depending on whether the mes-
enchymal and epithelial elements are uterine
(`homologous’, e.g. smooth muscle, endometrial
stroma) or non-uterine (`heterologous’ e.g. striated
muscle, cartilage, bone) in origin (Table 1). Car-
cinosarcomas, containing malignant components
from both cell lines, are commoner than the pure
uterine sarcomas but still comprise less than 2% of
uterine tumours.
1,2 They are rare during repro-
ductive life, with a median incidence at age 65.
3
Risk factors overlap with endometrial cancer
(namely hypertension, diabetes and nulliparity) but
to a lesser degree.
2 The most reliable risk factor is
previous pelvic irradiation, although the true inci-
dence (between 5 and 35% at ten years) is dis-
puted.
4
Staged in the same manner as endometrial
tumours, treatment of early disease is by total
abdominal hvsterectomy and bilateral salpingo-
oophorectomy with peritoneal cytological sampling.
5
The role of lymphadenectomy remains unclear.
Prognostic indicators such as the degree of mitotic
activity, cellular atypia and cervical involvement are
less useful than in endometrial tumours,
6 although
vascular involvement and positive cytology are of
sinister portent.
7
Whether to treat with adjuvant radiotherapy or
chemotherapy (and indeed the optimum timing and/
or agent used) is still uncertain, with distant recur-
rence a perpetual problem.
2 Advanced (stage III and
IV) or recurrent disease has an appalling prognosis
regardless of treatment.
8
Speci® c GnRH receptors have been demonstrated
in normal myometrium, leiyomyomata,
9 epithelial
ovarian and endometrial cancer cells,
10± 12 and a
number of human cancer cell lines (MCF-7, MDA-
MB-231, LNCaP).
13 In vitro inhibition of growth by
GnRH analogues has been clearly demonstrated in
ovarian tumours
14 and there has been some early
(and limited) success in treating advanced endome-
trial and ovarian cancer with Goserelin.
15,16
In the above cases the clinical situation was
judged to warrant intervention with as few side-
effects as possible. Both women were in® rm and
reluctant to undergo radiotherapy or aggressive
chemotherapy; adverse effects of GnRH treatment
were thought to be unlikely and treatment com-
menced on the ® rst Hippocratic principle.
There was con® rmed clinical remission in both
cases lasting over a year with no signi® cant side-
effects. We suggest that further research in elucidat-
ing the role of GnRH analogues in the treatment of
these rare tumours is indicated at both a cellular and
therapeutic level.
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